Glioblastoma

From 1 June 2021, MVASI® brand for bevacizumab will replace the Avastin® brand for all PBS listed items.

This has reduced the authority level, and bevacizumab is now listed as unrestricted benefit. Authority approval isn’t required for prescribing the listed quantity and repeats.

More information

Visit the PBS Schedule, or contact the PBS General Enquiries line for further information.

Page last updated: 1 June 2021